missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Teprotumumab Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody
Brand: Invitrogen™ MA558639
This item is not returnable.
View return policy
Description
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. 8 Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received breakthrough therapy designation from the FDA in 20163 and was approved by the FDA in January 2020 for the treatment of TED. 7 Thyroid eye disease is a potentially debilitating complication of Graves' Disease involving inflammation and tissue remodeling behind the eye, and previous treatment options typically involved multiple invasive surgeries - teprotumumab is the first pharmaceutical ever approved for the treatment of TED and therefore represents a significant step forward in the treatment this disease.
Specifications
| Teprotumumab | |
| Recombinant Monoclonal | |
| Unconjugated | |
| RO4858696-000 | |
| Protein A | |
| RUO | |
| Human | |
| Antibody | |
| IgG1 |
| ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance | |
| 1 mg/mL | |
| 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2 | |
| Human | |
| 100 μg | |
| Primary | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Lyophilized |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction